Scholarlink

Background <p>Consistent with WHO guidance Zimbabwe is transitioning from annual single visit screen-and-treat using visual inspection with acetic acid and cervicography (VIAC) to HPV testing every three years to screen women living with HIV (WLHIV) for cervical cancer.</p> Methods <p>We administered a questionnaire at three public-sector facilities in Zimbabwe to understand reasons why WLHIV accept or decline VIAC and preferences for implementation of HPV testing.</p> Results <p>A total of 451 WLHIV completed the questionnaire, of whom 414 (91.8%) accepted VIAC screening and 37 (8.2%) declined screening. Close to 50% of the 37 women who declined screening indicated a preference for HPV testing. The majority of WLHIV (76.3%) had known their HIV positive status for ≥ 5 years and nearly all (99.8%) were on antiretroviral therapy. Among the 414 WLHIV accepting VIAC screening, 323 (78.0%) were re-screening, and 91 (22.2%) were screening for the first time. WLHIV accepting VIAC re-screening were motivated by healthcare workers helping them feel secure about their health (45.8%), compliance with annual screening recommendations (39.6%), and encouragement from a healthcare worker (8.0%). Those accepting VIAC screening for the first time were motivated by encouragement from a healthcare worker (39.6%), compliance with annual screening recommendations (38.5%), and helping them feel secure about their health (17.6%). When asked what screening approach they would prefer in the future, the majority of women accepting re-screening (70.3%) and first-time screeners (89%) indicated a preference for continuing with VIAC screening. The 93 WLHIV with a screening history who indicated a preference for HPV testing were evenly split between preferring provider-collected sampling (13.9%) and self-collected sampling at the health facility (13.6%). Fear of physical discomfort of a pelvic exam (54.1%), worry about the screening result (13.5%), and perceived side effects of VIAC (10.8%) were the most common reasons given by the 37 WLHIV who declined VIAC.</p> Conclusions <p>Facilities transitioning to HPV testing will need to incorporate client-centered education that acknowledges existing individual commitment to VIAC, explains the benefits of HPV testing, and offers HPV self-sampling for WLHIV who are hesitant to undergo a pelvic exam.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Motivations and hesitations for cervical cancer screening: considerations for scale-up of human papilloma virus (HPV) testing within HIV care in Zimbabwe

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年6月19日

查看全文
  • Phibion Manyanga,
  • Anjali Vasavada,
  • Sandra Murwira,
  • Lucia Gondongwe,
  • Ponesai Nyika,
  • Brian K. Moyo,
  • Gloria Gonese,
  • Batsirai Makunike-Chikwinya,
  • Stefan Wiktor,
  • Kerry A. Thomson

摘要

Background

Consistent with WHO guidance Zimbabwe is transitioning from annual single visit screen-and-treat using visual inspection with acetic acid and cervicography (VIAC) to HPV testing every three years to screen women living with HIV (WLHIV) for cervical cancer.

Methods

We administered a questionnaire at three public-sector facilities in Zimbabwe to understand reasons why WLHIV accept or decline VIAC and preferences for implementation of HPV testing.

Results

A total of 451 WLHIV completed the questionnaire, of whom 414 (91.8%) accepted VIAC screening and 37 (8.2%) declined screening. Close to 50% of the 37 women who declined screening indicated a preference for HPV testing. The majority of WLHIV (76.3%) had known their HIV positive status for ≥ 5 years and nearly all (99.8%) were on antiretroviral therapy. Among the 414 WLHIV accepting VIAC screening, 323 (78.0%) were re-screening, and 91 (22.2%) were screening for the first time. WLHIV accepting VIAC re-screening were motivated by healthcare workers helping them feel secure about their health (45.8%), compliance with annual screening recommendations (39.6%), and encouragement from a healthcare worker (8.0%). Those accepting VIAC screening for the first time were motivated by encouragement from a healthcare worker (39.6%), compliance with annual screening recommendations (38.5%), and helping them feel secure about their health (17.6%). When asked what screening approach they would prefer in the future, the majority of women accepting re-screening (70.3%) and first-time screeners (89%) indicated a preference for continuing with VIAC screening. The 93 WLHIV with a screening history who indicated a preference for HPV testing were evenly split between preferring provider-collected sampling (13.9%) and self-collected sampling at the health facility (13.6%). Fear of physical discomfort of a pelvic exam (54.1%), worry about the screening result (13.5%), and perceived side effects of VIAC (10.8%) were the most common reasons given by the 37 WLHIV who declined VIAC.

Conclusions

Facilities transitioning to HPV testing will need to incorporate client-centered education that acknowledges existing individual commitment to VIAC, explains the benefits of HPV testing, and offers HPV self-sampling for WLHIV who are hesitant to undergo a pelvic exam.